Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Carcinoma, Intraductal, Noninfiltrating 6Neoplasms 4Neoplasm Metastasis 3Breast Neoplasms, Male 3Breast Diseases 3Breast Carcinoma In Situ 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Cancer Metastatic 2Sexual Dysfunction, Physiological 1Seizures 1Multiple Endocrine Neoplasia Type 1 1Locoregional Recurrence 1Lethal Congenital Contracture Syndrome 2 1Inflammatory Breast Neoplasms 1Hypogonadism 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Granulosa Cell Ovarian Cancer 1Fallopian Tube Neoplasms 1Erectile Dysfunction 1Epilepsy 1Endometrial Stromal Tumors 1ER+ Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasm Female 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2olaparib 1exemestane 1abemaciclib 1X-Rays 1Tamoxifen 1Letrozole 1Gonadotropin-Releasing Hormone 1Fulvestrant 1Fluorodeoxyglucose F18 1Estradiol 1Biopsy 1Anastrozole 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anatomic Stage III Breast Cancer AJCC v8 × Anastrozole × Clear all
NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

University of Washington

Phase 2 Recruiting
60 enrolled
Breast

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡